It checked a few surface-level boxes, but it didnt deliver the value or support patients deserve, especially at this price point
Location: Plainsboro, New JerseyWarning Letter Date: September 9, 2025FDA Department Issuing Warning: Center for Drug Evaluation and Research (CDER)Type of Warning: False & Misleading Claims/Misbranded DrugsSubject of Violation: An Oprah Special: Shame, Blame, and the Weight Loss Revolution, regarding Wegovy (semaglutide) injection, for subcutaneous use, Ozempic (semaglutide) injection, for subcutaneous use, and Victoza (liraglutide) injection, for subcutaneous use.FDA Warning: In the program, which aired on television in 2024 and until recently was available continuously on the ABC website and through various streaming services, Novo Nordisk promoted Wegovy, Ozempic, and Victoza in a manner that failed to present the serious risks of these drug products in a truthful and nonmisleading manner
10.1007/s00213-019-05357-2 103
One subject with poor blood sugar control (fasting plasma glucose values 500 mg/dL) at baseline was excluded as the primary investigator considered the risk of hyperglycemic hyperosmolar nonketotic coma
It works by blocking an enzyme called NNMT (nicotinamide N-methyltransferase)